Gestational trophoblastic disease

Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):357-70. doi: 10.1016/j.bpobgyn.2011.11.009. Epub 2012 Jan 28.

Abstract

Most women with gestational trophoblastic disease are of reproductive age. Because the disease is readily treatable with favourable prognosis, fertility becomes an important issue. Hydatidiform mole is a relatively benign disease, and most women do not require chemotherapy after uterine evacuation. A single uterine evacuation has no significant effect on future fertility, and pregnancy outcomes in subsequent pregnancies are comparable to that of the general population, despite a slight increased risk of developing molar pregnancy again. If women develop persistent trophoblastic disease, single or combined chemotherapy will be needed. Although ovarian dysfunction after chemotherapy is a theoretical risk, a term live birth rate of higher than 70% has been reported without increased risk of fetal abnormalities. Successful pregnancies have also been reported after choriocarcinoma. Only a few case reports have been published on fertility-sparing treatment in placental-site trophoblastic tumour, and the successful rate is about 67%. Women are advised to refrain from pregnancy for at least 6 months after a molar pregnancy, and at least 12 months after a gestational trophoblastic neoplasia. Most of the contraceptive methods do not have an adverse effect on the return of fertility. Finally, at least one-half of these women suffer from some form of psychological or sexual problems. Careful counselling and involvement of a multi-disciplinary team are mandated.

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Contraception
  • Dilatation and Curettage
  • Female
  • Fertility Preservation*
  • Gestational Trophoblastic Disease / complications
  • Gestational Trophoblastic Disease / psychology
  • Gestational Trophoblastic Disease / therapy*
  • Humans
  • Infertility, Female / etiology
  • Infertility, Female / prevention & control
  • Neoplasm Recurrence, Local / therapy*
  • Organ Sparing Treatments*
  • Ovary / drug effects
  • Ovary / physiopathology
  • Pregnancy
  • Pregnancy Outcome

Substances

  • Antineoplastic Agents